ReviewBiotechnology journal2014
Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack.
Review in Biotechnology journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Examining the gene network and prognostic biomarkers in the onset of colorectal cancer in stool samples using machine learning.Discover oncology · 2026Article
- Transcriptomics Based Network Analyses and Molecular Docking Highlighted Potentially Therapeutic Biomarkers for Colon Cancer.Biochemical genetics · 2023Article
- Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?Frontiers in oncology · 2021Review
- Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.Cancer biomarkers : section A of Disease markers · 2020Article
- PlatformTM, a standards-based data custodianship platform for translational medicine research.Scientific data · 2019Article
- Data and knowledge management in translational research: implementation of the eTRIKS platform for the IMI OncoTrack consortium.BMC bioinformatics · 2019Article
- Computational Approaches in Theranostics: Mining and Predicting Cancer Data.Pharmaceutics · 2019Review
- The Innovative Medicines Initiative -10 Years of Public-Private Collaboration.Frontiers in medicine · 2019Review
- The Key Genes of Chronic Pancreatitis which Bridge Chronic Pancreatitis and Pancreatic Cancer Can be Therapeutic Targets.Pathology oncology research : POR · 2018Article
- Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.Bioengineering (Basel, Switzerland) · 2017Article
- Epigenetic Biomarkers in Colorectal Cancer.Molecular diagnosis & therapy · 2017Review
- Models of Models: A Translational Route for Cancer Treatment and Drug Development.Frontiers in oncology · 2017Article
- Omics approaches to individual variation: modeling networks and the virtual patient.Dialogues in clinical neuroscience · 2016Article
- Novel Holistic Approaches for Overcoming Therapy Resistance in Pancreatic and Colon Cancers.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2016Review
- Cancer Metabolism and Drug Resistance.Metabolites · 2015Review
- [Individualized, personalized and stratified medicine: a challenge for allergology in ENT?].HNO · 2015Article
- Building SuperModels: emerging patient avatars for use in precision and systems medicine.Frontiers in physiology · 2015Article
- Challenges and Opportunities for Exploring Patient-Level Data.BioMed research international · 2015Review
- Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics.Genome medicine · 2014Article
- Precision medicine in colorectal cancer.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The post-genomic era promises to pave the way to a personalized understanding of disease processes, with technological and analytical advances helping to solve some of the world's health challenges. Despite extraordinary progress in our understanding of cancer pathogenesis, the disease remains one of the world's major medical problems. New therapies and diagnostic procedures to guide their clinical application are urgently required. OncoTrack, a consortium between industry and academia, supported by the Innovative Medicines Initiative, signifies a new era in personalized medicine, which synthesizes current technological advances in omics techniques, systems biology approaches, and mathematical modeling. A truly personalized molecular imprint of the tumor micro-environment and subsequent diagnostic and therapeutic insight is gained, with the ultimate goal of matching the "right" patient to the "right" drug and identifying predictive biomarkers for clinical application. This comprehensive mapping of the colon cancer molecular landscape in tandem with crucial, clinical functional annotation for systems biology analysis provides unprecedented insight and predictive power for colon cancer management. Overall, we show that major biotechnological developments in tandem with changes in clinical thinking have laid the foundations for the OncoTrack approach and the future clinical application of a truly personalized approach to colon cancer theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.